Kidney Cancer | Tumor

FDA Grants Priority Review to Keytruda Combo as Frontline Treatment for Kidney Cancer

February 15th 2019

The Food and Drug Administration granted a priority review to Keytruda (pembrolizumab) in combination with Inlyta (axitinib) as a frontline treatment for advanced renal cell carcinoma.

FDA Grants Priority Review to Bavencio Plus Inlyta to Treat Advanced Renal Cell Carcinoma

February 12th 2019

The Food and Drug Administration granted a priority review to Bavencio (avelumab) in combination with Inlyta (axitinib) to treat patients with advanced renal cell carcinoma (RCC).

Aerobics, Strength Exercises Improve Quality of Life in Kidney Cancer Survivors

January 28th 2019

Meeting combined exercise guidelines improved quality of life in kidney cancer survivors; however, few individuals reported that they actually follow such guidelines.

Immunotherapy Pair Good for Some, Not All, With Kidney Cancer

January 25th 2019

Yervoy plus Opdivo is a good combination for many patients with kidney cancer, though some individuals should steer clear of the regimen.

Obesity Factors May Increase Kidney Cancer Risk

January 25th 2019

Certain factors – such as diastolic blood pressure and fasting insulin – were found to be associated with renal cell carcinoma.

Occupational Gasoline Exposure May Increase Kidney Cancer Risk

January 15th 2019

People who have experienced high exposures to gasoline might be at an increased risk for kidney cancer, according to recent research.

Staying Vigilant to Manage Treatment-Related Side Effects in Kidney Cancer

January 14th 2019

Treatment side effects are typically manageable for patients with metastatic kidney cancer, but patients must have open communication with their health care team about them.

Contrary to Previous Studies, Sex May Not Impact Efficacy of Immunotherapy

January 10th 2019

A recent meta-analysis has found no noticeable difference in immunotherapy’s efficacy based on patient sex.

Fotivda Lengthens Time to Disease Progression in Renal Cell Carcinoma

November 19th 2018

The phase 3 TIVO-3 trial – designed to evaluate the efficacy of Fotivda in patients with renal cell carcinoma – met its primary endpoint of improved progression-free survival.

CURE New Issue Alert: Fall 2018

November 14th 2018

We've got a sneak peek at what’s inside our Fall 2018 issue.

Immunotherapy Is 'Here to Stay' in Kidney Cancer

November 14th 2018

Checkpoint inhibitors are moving into the treatment realm of renal cell carcinoma; however, questions still remain.

Distress Levels High Among Patients With Common Form of Kidney Cancer

November 8th 2018

Many patients with renal cell carcinoma, the most common type of kidney cancer, experience high levels of distress, according to study findings published in BJU International.

A State of Flux for Kidney Cancer

November 6th 2018

Targeted drugs are controversial in early-stage kidney cancer, but play a more important role in treating advanced disease.

Germline Mutations in Non-Clear Cell Renal Cell Carcinoma May Direct Systemic Therapy

October 16th 2018

More than 20 percent of patients with non–clear cell renal cell carcinoma (RCC) had a germline mutation, of which half had the potential to direct systemic therapy.

New Approach May Spare Some with Kidney Cancer from Undergoing Surgery

October 16th 2018

Experts at Roswell Park Comprehensive Cancer Center discovered a way to assess if a kidney tumor is benign or malignant, potentially sparing many from having to undergo surgery.

NCCN Updates Guidelines for Kidney Cancer

October 15th 2018

The National Comprehensive Cancer Network updated its Clinical Practice Guidelines to add two new options for the frontline treatment of patients with kidney cancer.

Cancer Researchers Win Nobel Prize

October 2nd 2018

Immunotherapy pioneers James P. Allison and Dr. Tasuku Honjo have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

Monitoring Immunotherapy's Side Effects in Genitourinary Cancers

May 24th 2018

PD-1 and PD-L1 inhibitors are generally well-tolerated, so most patients face little or no issues with the drugs. However, there are still some things to look out for.

Immunotherapy in GU Cancers: Combinations Are the Next Step

May 4th 2018

Immunotherapy is making landmark change in the treatment of patients with genitourinary (GU) cancers, with bladder cancer being the pioneer in the field, having five FDA-approved checkpoint inhibitors. But kidney cancer is not far behind, with a breakthrough therapy designation granted for a Keytruda (pembrolizumab) combination this past January.

FDA Approves Immunotherapy Duo for Kidney Cancer

April 16th 2018

The Food and Drug Administration (FDA) approved the immunotherapy combination of Yervoy (ipilimumab) plus Opdivo (nivolumab) to treat patients with intermediate- or poor-risk advanced renal cell carcinoma in the frontline setting.

Patient Education Key in Flexible Dosing Schedule for Opdivo

March 22nd 2018

After a recent FDA approval for an additional dosing schedule option for Opdivo, patients must be educated on the potential side effects that may occur between prolonged visits.

The Future of Kidney Cancer Management

March 8th 2018

Practical Advice for Patients With Kidney Cancer

March 8th 2018

Second-Line Therapeutic Options for Kidney Cancer

March 8th 2018

First-Line Kidney Cancer Treatment: Targeted Therapy

March 8th 2018

Kidney Cancer: Considering First-Line Treatment Options

March 8th 2018

Frontline Surgical Resection for Kidney Cancer

March 8th 2018

Approaching the Treatment of Kidney Cancer

March 8th 2018

Getting a Diagnosis for Kidney Cancer

March 8th 2018

Kidney Cancer Support & Resources

March 8th 2018